Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) EBIT: 2009-2024

Historic EBIT for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $1.4 billion.

  • UNITED THERAPEUTICS's EBIT rose 13.23% to $388.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 16.73%. This contributed to the annual value of $1.4 billion for FY2024, which is 16.21% up from last year.
  • UNITED THERAPEUTICS's EBIT amounted to $1.4 billion in FY2024, which was up 16.21% from $1.2 billion recorded in FY2023.
  • UNITED THERAPEUTICS's EBIT's 5-year high stood at $1.4 billion during FY2024, with a 5-year trough of $555.9 million in FY2021.
  • Over the past 3 years, UNITED THERAPEUTICS's median EBIT value was $1.2 billion (recorded in 2023), while the average stood at $1.2 billion.
  • Per our database at Business Quant, UNITED THERAPEUTICS's EBIT spiked by 416.42% in 2020 and then dropped by 6.35% in 2021.
  • Yearly analysis of 5 years shows UNITED THERAPEUTICS's EBIT stood at $593.6 million in 2020, then dropped by 6.35% to $555.9 million in 2021, then surged by 76.24% to $979.7 million in 2022, then climbed by 20.95% to $1.2 billion in 2023, then increased by 16.21% to $1.4 billion in 2024.